VANCOUVER, BC – Chemistree Technology Inc. (CSE: CHM) (CSE: CHM.WT) (OTCQB: CHMJF) (the “Company” or “Chemistree”) is pleased to confirm that investee company ImmunoFlex Therapeutics Inc. (“ImmunoFlex”™), today announced that it has completed and analyzed its clinical trial of 21 patients, aged 60 to 70 years. The exploratory trial was the latest of several small trials where ImmunoFlex has focused on analysing immune system modulation at a genomic level resulting from treatment with compounds including CBD, THC, NAC and several other widely available compounds.
“The research we completed is exploratory but the results are consistent with our earlier research. We are excited about the potential application of these products. Restoring immunocompetence in people has the potential to treat several diseases including COVID long haul, other viral-induced diseases, and to provide vaccine potentiation. Additional studies in this area are ongoing,” said ImmunoFlex CEO Chris Wagner.
In this latest study, traditional blood chemistry markers were not informative; however, genomic analysis of the immune system’s T cell receptor recognition regions (called CDR3’s) extracted from patient RNA showed immune system changes resulting from treatment. In one particular group, all patients showed consistent results across multiple genomic analyses. ImmunoFlex’s believes that the immune system changes observed in this clinical study are beneficial changes with the potential to improve immune system competence.
ImmunoFlex has submitted non-provisional (USA) and PCT (international) patent applications based on the research carried out by ImmunoFlex in 2020 and 2021.
Chemistree President, Karl Kottmeier commented “We are pleased that ImmunoFlex has made considerable progress since our foundational investment 12 months ago. Their ground-breaking research is amongst the first we have seen showing demonstrable clinical benefit of CBD, THC and NAC for the immune system. We look forward to the next chapters in their development”.
ImmunoFlex™ works with the immune system to strengthen, support, and enhance our body’s natural surveillance and response system. By combining existing compounds using genomics we create patent-pending, premium, immune-boosting products. Learn more at www.immunoflex.com
About Chemistree Technology Inc.
Chemistree Technology Inc. is an investment company with holdings in the U.S. cannabis sector, real estate, and a consumer-targeted biotechnology venture. The Company’s corporate strategy is to focus on opportunistic investments across a broad range of industries, and is seeking to invest in early stage, promising companies where it may be the lead investor and can additionally provide investees with advisory services, mentoring and access to the Company’s management expertise. For more information, visit www.Chemistree.ca